ASPC

ASPAC III Acquisition Corp. 10-Q Summary

Business Context and Reporting Period

ASPAC III Acquisition Corp. (the "Company") is a blank check company incorporated in the British Virgin Islands, formed to effect a merger or business combination with one or more businesses, specifically targeting the Environmental, Sustainability, and Governance (ESG) and material technology sectors. The reporting period covers the quarter and six months ended June 30, 2025. The Company consummated its Initial Public Offering (IPO) in November 2024 and has not yet commenced operations other than identifying a target.

Key Financial Metrics

Note: The Company has no operating revenue. Net income is derived primarily from interest earned on the Trust Account.

Material Changes vs. Prior Period

• Profitability Shift: The Company reported a net income of $793,141 for the six months ended June 30, 2025, compared to a net loss of $8,000 for the same period in 2024. This change is driven by significant interest income ($1.29M) generated from the Trust Account following the November 2024 IPO.
• Expense Increase: General and administrative expenses rose to $500,914 for the six months ended June 30, 2025, from $8,000 in the prior year period, reflecting the costs of being a public company and pursuing a business combination.
• Debt Repayment: The Company fully repaid a $276,221 promissory note to a related party on January 24, 2025. As of June 30, 2025, there is no outstanding balance on this note.
• Trust Account Growth: Investments held in the Trust Account increased from $60,356,959 at December 31, 2024, to $61,624,847 at June 30, 2025, due to accrued interest.

Outlook, Management Commentary, and Risks

• Proposed Business Combination: On May 23, 2025, the Company entered into a Merger Agreement with Bioserica International Limited ("Bioserica"), a developer of bio-based antimicrobial materials. The aggregate consideration is $217,860,000, payable in newly issued shares. This follows the termination of a prior agreement with HD Education Group Limited in May 2025.
• Going Concern: Management has determined that the Company's ability to continue as a going concern is subject to substantial doubt if it cannot complete a business combination by November 12, 2025 (12 months from IPO closing). If no combination is completed, the Company will liquidate and redeem public shares.
• Liquidity: Liquidity is currently satisfied by cash held outside the Trust Account ($1.07M) and potential working capital loans from the Sponsor. The Company may need additional financing to complete the Bioserica transaction or to cover redemption obligations.
• Risks: Risks include the failure to consummate the Bioserica merger, inability to raise additional financing, and global economic uncertainties affecting the ability to complete a transaction.

Investor Verification Checklist

• Merger Status: Verify the current status of the Merger Agreement with Bioserica International Limited and whether all conditions for closing have been met.
• Redemption Rights: Confirm the number of public shares subject to redemption and the current per-share redemption value in the Trust Account.
• Extension Options: Review the terms for extending the combination period (up to 18 months total) and the required deposit amounts ($550,000 per 3-month extension) from the Sponsor.
• Share Structure: Note the distinction between Class A shares subject to redemption (6,000,000 shares) and Class B founder shares (1,500,000 shares), including the 20% ownership cap and anti-dilution provisions.
• Going Concern: Assess the Company's cash runway outside the Trust Account against the timeline for the proposed merger or liquidation.